
GLP-1 is 30-amino acid peptide that is secreted from the intestine in response to food intake. The release mechanism involves luminal exposure to as well as absorption and metabolism of the major nutrients. It functions mainly as a part of the ileal brake mechanism whereby nutrient entry in distal segments of the small intestine inhibit gastrointestinal secretion and motility as well as appetite and food intake, signalling nutritional abundance. It also functions as a second line incretin hormone. It acts on the brain via sensory vagal afferents, but also interacts with exposed neurons expressing the GLP-1 receptor in the circumventricular organs, in turn activating brain nuclei involved in appetite regulation and reward. High doses of GLP-1 cause nausea and vomiting, but slow dosing titration mitigates this. GLP-1 Receptor Agonists owe their actions to these physiological mechanisms and therefore represent powerful antidiabetic agents (A1c levels below 5.7%) and cause major weight loss (up to 20%), but also appear to reduce the systemic low-grade inflammation of obesity and type 2 diabetes and to exert beneficial action on the blood vessels, providing the GLP-1RAs with preventive effects on cardiovascular, hepatic, renal and central nervous system complications. Orally active GLP-1rAs have also been developed. It is emphasized that GLP-1RA therapy should be accompanied by lifestyle changes for efficacy and to prevent side effects of the weight loss. In addition, any prescription of a GLP-1RA should include a plan to mitigate adverse effects of treatment termination. Nevertheless, GLP-1RAs represent a major breakthrough in the therapy of metabolic disease and are now included among the essential medicines of the WHO.
Diet and other lifestyle factors are central to diabetes prevention and management. Effective dietary and lifestyle support requires consideration of differences in pathophysiology, food culture, and living circumstances. This narrative review summarizes our research integrating clinical medicine, nutritional epidemiology, and behavioral science, with a particular focus on diet quality. Analyses of large US cohorts showed that higher-quality plant-based diets were associated with lower risks of stroke and mortality. In longitudinal biomarker analyses, increases in healthful plant-based diet scores were associated with favorable changes in high-sensitivity C-reactive protein, whereas increases in unhealthful plant-based diet scores were associated with unfavorable changes in inflammatory biomarkers. Metabolite profiles related to healthful plant-based diets were also associated with lower type 2 diabetes risk. Building on earlier work on adiponectin and type 1 diabetes, our studies in Japan showed that even small weight changes were associated with type 2 diabetes risk, depending on age and baseline body mass index. Visceral fat correlated with ectopic fat, and fast eating and eating late at night were associated with greater pancreatic fat deposition. In older adults, lower sweet taste sensitivity was associated with frailty and poorer mental health-related quality of life. These findings suggest that diet quality and lifestyle should be assessed together with each person’s metabolic characteristics and living circumstances. Intervention and implementation studies based on this largely observational evidence are the next step toward individualized diabetes prevention and care.
Experimental studies suggest that fibroblast growth factor 21 (FGF21) is involved in pathways related to peroxisome proliferator-activated receptor alpha (PPARα) activation, whereas elevated circulating FGF21 has also been associated with metabolic stress and kidney dysfunction. We examined the associations of FGF21 with renal parameter changes following the initiation of pemafibrate, a selective PPARα modulator, in patients with type 2 diabetes mellitus (T2DM). In this retrospective study using prospectively collected blood samples, 81 patients with T2DM who initiated pemafibrate and continued treatment for ≥ 2 years were analyzed. Clinical data and serum high-sensitivity C-reactive protein (hsCRP) and FGF21 levels were assessed at baseline and two years. The main outcomes were changes in estimated glomerular filtration rate (eGFR) and log-transformed urinary albumin-to-creatinine ratio (UACR). Multivariable linear regression analyses were performed. During the two-year observation period, triglyceride, hsCRP, and UACR levels decreased, whereas FGF21 increased; eGFR remained stable. The change in eGFR was more favorable in patients with baseline eGFR of 30 to < 60 mL/min/1.73 m2 than in those with eGFR ≥ 60 mL/min/1.73 m2. Higher baseline FGF21 and greater increases in FGF21 remained associated with less favorable changes in eGFR and UACR in multivariable analyses. Higher baseline FGF21 and greater increases in FGF21 were associated with less favorable renal parameter changes after pemafibrate initiation. Because this observational study lacked a control group, causal effects cannot be inferred. Prospective controlled studies are needed to determine the clinical significance of circulating FGF21.
In this study, we conducted an exploratory analysis to examine the effects of weight-bearing high-intensity interval training (HIIT) performed before evening meals on postprandial glucose concentrations, comparing it to pedaling exercise and sitting at rest. Eleven individuals with type 2 diabetes completed three experimental conditions: the H condition, in which they performed weight-bearing exercise-based HIIT before dinner; the P condition, in which they engaged in pedaling exercise before dinner; and the C condition, in which they consumed dinner without structured physical activity. The primary outcome was the incremental area under the curve of glucose concentration (iAUC) up to 3 h after dinner. The main effect of condition on iAUC was not statistically significant (F[2, 18] = 2.35, p = 0.124). However, pairwise comparisons demonstrated large effect sizes favoring the intervention conditions over the C condition, with within-participant differences of 2845.3 (95
Nationwide Japanese claims studies have documented regional variation in quantitative urinary albumin or protein testing, but it is unclear whether geographic ordering persists over time or depends on the denominator used. We evaluated the persistence of prefectural ordering in billed urinary albumin quantification and examined its robustness using a population-based denominator. This ecological provider-location study used National Database Open Data for 47 prefectures. FY2015-FY2022 was the primary historical interval; FY2023-FY2024 was a scope-aligned extension. The primary metric was urinary albumin quantification billing counts per 1,000 HbA1c billing counts. A sensitivity analysis used counts per 100,000 total population. Equal-weight dispersion, endpoint Spearman correlations, Kendall’s W across annual ranks, and cross-metric rank correspondence were calculated. During FY2015-FY2022, the national primary metric increased from 26.20 to 33.54 (+ 28.0